HOME >> MEDICINE >> NEWS
Trial shows malaria vaccine could protect young children from disease for 18 months

The RTS, S/AS02A vaccine could protect young African children against a range of clinical disease caused by the malaria parasite for at least 18 months, concludes a randomised trial published online today (Tuesday November 15, 2005) by The Lancet.

Early trials of the RTS, S/AS02A vaccine have shown that the vaccine is safe, well tolerated, and can trigger an immune response. In one of the trials, involving over 2000 Mozambican children aged 1-4 years, Pedro Alonso (University of Barcelona, Spain) and colleagues found that after 6 months' follow-up the vaccine reduced the risk of clinical malaria by 30%, delayed time to first infection by 45%, and reduced the risk of severe malaria by 58%. In the latest study the investigators followed-up the children for a further 12 months. They found that the efficacy of the drug did not wane and that protection against clinical malaria lasted for at least 18 months after vaccination. The study shows that the vaccine reduces the risk of clinical malaria by 35% and nearly halves the risk of severe malaria over a period of 18 months.

Professor Alonso states: "Our results show that the RTS,S/AS02A candidate malaria vaccine confers partial protection for at least 18 months against a range of clinical diseases caused by P falciparum in children living in a rural malaria endemic area of African The combination of sustained protection together with substantial prevention of the severe forms of malaria marks RTS, S/AS02A as a promising vaccine candidate and strongly suggests that malaria vaccines have an important role as future public-health instruments."

The publication coincides with a presentation at the Fourth Multilateral Initiative on Malaria Pan-African Malaria Conference 2005 in Yaounde, Cameroon.


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
15-Nov-2005


Page: 1

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. ENDEAVOR III Trial reports key findings on new-generation stent
5. NIH names Clinical Trial Units for the Microbicide Trials Network
6. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
7. The Public Library of Science launches the new open access journal PLoS Clinical Trials
8. Trial shows vaccine against cervical cancer provides long-term protection
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's ... organizations. DocuSyst provides a cloud hosted environment for FileHold software that is ... with various 3rd party applications using the FileHold web services API. DocuSyst also ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... share this important news! AHCC and the Home Health and Hospice ICD-10 Transition ... designee for official ICD coding guidance and clarifications, to address concerns over the ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 ... in honor of his birthday on February 10th. During this time, people can ... known by over 250,000 people from over 40 different countries as an “ordinary man ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... and Facial Plastics, has added Kybella® to his medical and surgical expertise. Technically ... newly approved FDA injectable medication used as a non-surgical alternative for reduction of ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... MEMPHIS, Tenn. , Feb. 8, 2016  A ... Hospital scientists has discovered details of how the ... cells triggers a particularly aggressive form of acute lymphoblastic ... cells, in which genetic mutations trigger overproduction of immature ... --> The discoveries of the malfunction underlying the ...
(Date:2/8/2016)... Feb. 8, 2016  As part of a major growth ... the appointment of Lori Chmura as President of ... in the industry, Chmura,s extensive experience in the medical device ... Dune Medical Devices. --> ... for leading all sales, marketing and operational functions in the ...
(Date:2/8/2016)... Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ... 2016, ended December 31, 2015, the Company achieved revenue of ... the same quarter in fiscal 2015. --> ... of fiscal year 2016 was $2,068,635, or $.03 per share, ... per share, in the Q2 of fiscal year 2015. Gross ...
Breaking Medicine Technology:
Cached News: